Processing your request


please wait...

Case Page

 

Case Status:    DISMISSED    
On or around 07/21/2021 (Court's order of dismissal)

Filing Date: July 23, 2019

According to the Complaint, Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer and other major diseases. During the Class Period, Karyopharm’s lead drug candidate was selinexor, an oral selective inhibitor of nuclear export for the treatment of cancer indications with significant unmet clinical need, initially to be used for the treatment of blood cancers.

The Complaint alleges that during the Class Period, Defendants falsely represented the safety and efficacy of selinexor. Specifically, the Complaint alleges Defendants' material misrepresentations and omissions center on Defendants' claims regarding results from clinical trials for selinexor's treatment of patients with certain types of blood cancer.

This case was voluntarily dismissed on March 12, 2020. A related case continues under Docket 19-CV-11972.

On April 29, 2020, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on June 29. On October 22, Lead Plaintiff filed a second amended Complaint. Defendants filed a Motion to Dismiss the second amended Complaint on November 2. On July 21, 2021, the Court issued an Order granting Defendants' Motion to Dismiss. On August 20, Lead Plaintiff filed a notice appealing the Court's Dismissal Order.

The Court of Appeals issued an Order affirming the District Court's Dismissal Order on August 5, 2022.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.